MSFT 415.85 -0.4643% AAPL 228.66 0.1665% NVDA 145.315 -1.153% GOOGL 175.65 -1.3867% GOOG 177.07 -1.3977% AMZN 202.88 -0.8455% META 564.135 0.5427% AVGO 162.61 -1.6571% TSLA 342.2799 -1.0752% TSM 186.825 -1.5% LLY 754.385 3.3786% V 307.39 -1.4302% JPM 240.935 -0.8865% UNH 601.41 4.2305% NVO 105.52 2.8159% WMT 87.12 0.6005% LVMUY 121.8 -0.5471% XOM 119.97 1.1296% LVMHF 607.0 -0.9465% MA 512.64 -1.3129%
Last update at 2024-11-19T21:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 42.04M | -93.33500M | -229.61600M | -32.48700M | -32.35500M |
| Minority interest | 0.00000M | 0.00000M | 0.56M | 0.92M | 0.91M |
| Net income | 37.51M | -95.06100M | -229.34800M | -31.74100M | -31.44400M |
| Selling general administrative | 36.12M | 33.81M | 34.19M | 11.76M | 7.67M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 172.83M | 34.76M | 31.25M | 18.45M | 3.77M |
| Reconciled depreciation | 6.97M | 5.26M | 4.42M | 3.86M | 2.18M |
| Ebit | 29.95M | -86.29400M | -69.71500M | -33.01300M | -33.90200M |
| Ebitda | 46.34M | -75.35900M | -64.44100M | -28.36500M | -31.72600M |
| Depreciation and amortization | 16.38M | 10.94M | 5.27M | 4.65M | 2.18M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 29.95M | -86.29400M | -69.71500M | -33.01300M | -34.40900M |
| Other operating expenses | 142.88M | 121.05M | 100.97M | 51.46M | 38.18M |
| Interest expense | 8.28M | 1.73M | 0.29M | 0.17M | 0.02M |
| Tax provision | 4.55M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 9.42M | 5.67M | 0.85M | 0.79M | 0.51M |
| Net interest income | 1.14M | 3.95M | 0.56M | 0.62M | 0.49M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 4.55M | 1.73M | -0.26800M | -0.74600M | -2.96500M |
| Total revenue | 172.83M | 34.76M | 31.25M | 18.45M | 3.77M |
| Total operating expenses | 142.88M | 121.05M | 100.97M | 51.46M | 38.18M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 12.08M | -7.04100M | -159.90100M | 0.53M | 1.56M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 37.51M | -93.33500M | -229.61600M | -32.48700M | -32.35500M |
| Net income applicable to common shares | - | - | - | - | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 509.96M | 407.82M | 174.65M | 254.65M | 134.28M |
| Intangible assets | 1.52M | 1.63M | 1.31M | 0.91M | 1.01M |
| Earning assets | - | - | - | - | - |
| Other current assets | 7.12M | 13.84M | 6.41M | 0.79M | 0.67M |
| Total liab | 284.88M | 194.66M | 150.58M | 150.39M | 175.11M |
| Total stockholder equity | 225.08M | 213.16M | 24.06M | 104.26M | -41.85500M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 45.88M | 26.28M | 30.41M | 9.57M | 3.39M |
| Common stock | 0.85M | 0.77M | 0.63M | 0.63M | 1.16M |
| Capital stock | 0.85M | 0.77M | 0.63M | 0.63M | 1.16M |
| Retained earnings | -597.29300M | -500.29900M | -537.81300M | -462.25300M | -233.19400M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 218.47M | 148.52M | 132.99M | 207.53M | 103.35M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 156.55M | 106.45M | 95.15M | 60.61M | 69.30M |
| Current deferred revenue | 100.40M | 64.96M | 50.40M | 46.60M | 59.63M |
| Net debt | -203.07000M | -133.95700M | -123.14100M | -201.34300M | -100.11900M |
| Short term debt | 2.60M | 2.16M | 2.71M | 1.88M | 1.41M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 15.40M | 14.56M | 9.85M | 6.19M | 3.23M |
| Other stockholder equity | 823.17M | 714.18M | 565.19M | 573.34M | 190.94M |
| Property plant equipment | - | - | - | - | - |
| Total current assets | 449.37M | 377.15M | 152.21M | 238.99M | 124.00M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | - | - |
| Short term investments | 207.42M | 213.69M | 12.12M | 24.45M | 16.02M |
| Net receivables | 5.74M | 1.11M | 0.68M | 2.92M | 2.72M |
| Long term debt | - | - | - | - | - |
| Inventory | 10.62M | - | - | 3.30M | 1.24M |
| Accounts payable | 7.67M | 13.06M | 11.62M | 2.55M | 4.87M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1.63600M | -1.48100M | -3.94500M | -7.45900M | -0.77000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.02M | 2.54M | 0.64M | 0.73M | 1.26M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 60.59M | 30.67M | 22.44M | 15.65M | 10.28M |
| Capital lease obligations | 15.40M | 14.56M | 9.85M | 6.19M | 3.23M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -209.79100M | 7.49M | -15.94900M | -5.05900M | -13.51400M |
| Change to liabilities | - | - | - | - | - |
| Total cashflows from investing activities | - | - | - | - | - |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 123.71M | -2.61300M | 207.88M | -1.86200M | 23.65M |
| Change to operating activities | - | - | - | - | - |
| Net income | 37.51M | -93.33500M | -229.61600M | -32.48700M | -32.35500M |
| Change in cash | 15.53M | -74.53600M | 104.18M | 63.99M | 30.95M |
| Begin period cash flow | 132.99M | 207.53M | 103.35M | 39.37M | 8.41M |
| End period cash flow | 148.52M | 132.99M | 207.53M | 103.35M | 39.37M |
| Total cash from operating activities | 100.13M | -81.78400M | -85.61000M | 70.97M | 20.68M |
| Issuance of capital stock | 134.48M | 0.09M | 217.92M | 0.00000M | 23.65M |
| Depreciation | 6.97M | 5.26M | 4.42M | 3.86M | 2.18M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.42900M | 0.57M | -0.29400M | -0.56300M | -0.17500M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -7.93100M | 7.49M | -7.93900M | -5.05900M | -13.51400M |
| Change to netincome | - | - | - | - | - |
| Capital expenditures | 6.21M | 5.66M | 7.52M | 2.23M | 0.51M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 37.26M | -31.69800M | -25.28100M | 96.88M | 49.16M |
| Stock based compensation | 22.57M | 26.40M | 22.95M | 0.85M | 1.48M |
| Other non cash items | -8.70000M | 0.43M | 145.87M | 1.24M | -0.27100M |
| Free cash flow | 93.92M | -87.44100M | -93.13400M | 68.73M | 20.18M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | ||
|---|---|---|---|---|---|---|---|---|
| IMTXW immatics biotechnologies GmbH |
-0.14 23.33% | 0.46 | - | - | - | - | ||
| NVO Novo Nordisk A/S |
2.89 2.82% | 105.52 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
2.44 2.38% | 105.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.44 0.10% | 448.45 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-1.25 0.17% | 743.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076
| Name | Title | Year Born |
|---|---|---|
| Dr. Harpreet Singh | Chief Exec. Officer | NA |
| Dr. Hans-George Rammensee | Co-Founder, Head of the Scientific Advisory Board | NA |
| Dr. Toni Weinschenk | Co-Founder & Chief Innovation Officer | NA |
| Mr. Thomas Ulmer | Chief Financial Officer | NA |
| Ms. Jessica Mosby Ed.D. | Sr. Director HR & Operations | NA |
| Dr. Harpreet Singh Ph.D. | CEO, MD, Member of Management Board & Executive Director | 1975 |
| Dr. Toni Weinschenk Ph.D. | Co-Founder & Chief Innovation Officer | 1974 |
| Mr. Arnd Christ MBA | Chief Financial Officer | 1966 |
| Mr. Steffen Walter Ph.D. | Chief Operations Officer | 1977 |
| Mr. Edward A. Sturchio J.D. | General Counsel & Secretary | 1976 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...